Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Operations (2019 - 2025)

Keros Therapeutics' Cash from Operations history spans 7 years, with the latest figure at 27292000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 40.68% year-over-year to 27292000.0; the TTM value through Dec 2025 reached 107505000.0, up 166.83%, while the annual FY2025 figure was 107505000.0, 166.83% up from the prior year.
  • Cash from Operations reached 27292000.0 in Q4 2025 per KROS's latest filing, down from 3249000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 161171000.0 in Q1 2025 to a low of 46008000.0 in Q4 2024.
  • Average Cash from Operations over 5 years is 15504100.0, with a median of 25030500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: crashed 2299.09% in 2023, then surged 461.69% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 19565000.0 in 2021, then decreased by 9.6% to 21443000.0 in 2022, then decreased by 18.73% to 25459000.0 in 2023, then crashed by 80.71% to 46008000.0 in 2024, then skyrocketed by 40.68% to 27292000.0 in 2025.
  • Per Business Quant, the three most recent readings for KROS's Cash from Operations are 27292000.0 (Q4 2025), 3249000.0 (Q3 2025), and 29623000.0 (Q2 2025).